Cas no 108853-09-4 (Benzene,5-[2-(3,4-dimethoxyphenyl)ethyl]-1,2,3-trimethoxy-)
Benzene,5-[2-(3,4-dimethoxyphenyl)ethyl]-1,2,3-trimethoxy- Chemical and Physical Properties
Names and Identifiers
-
- Benzene,5-[2-(3,4-dimethoxyphenyl)ethyl]-1,2,3-trimethoxy-
- 5-[2-(3,4-dimethoxyphenyl)ethyl]-1,2,3-trimethoxybenzene
- 3,3',4,4',5-pentamethoxybibenzyl
- 3,4,5,3',4'-pentamethoxybibenzyl
- AC1MJ6CP
- Aloifol II dimethyl ether
- Benzene, 5-(2-(3,4-dimethoxyphenyl)ethyl)-1,2,3-trimethoxy-
- CHEMBL307158
- Chrysotobibenzyl
- gastrochilinin
-
- Inchi: 1S/C19H24O5/c1-20-15-9-8-13(10-16(15)21-2)6-7-14-11-17(22-3)19(24-5)18(12-14)23-4/h8-12H,6-7H2,1-5H3
- InChI Key: XKKZNLRWNSUNBW-UHFFFAOYSA-N
- SMILES: O(C)C1C(=C(C=C(C=1)CCC1C=CC(=C(C=1)OC)OC)OC)OC
Computed Properties
- Exact Mass: 332.16242
Experimental Properties
- PSA: 46.15
Benzene,5-[2-(3,4-dimethoxyphenyl)ethyl]-1,2,3-trimethoxy- Pricemore >>
| Related Categories | No. | Product Name | Cas No. | Purity | Specification | Price | update time | Inquiry |
|---|---|---|---|---|---|---|---|---|
| Ambeed | A1959993-5mg |
Chrysotobibenzyl |
108853-09-4 | 98% | 5mg |
$693.0 | 2025-03-01 |
Benzene,5-[2-(3,4-dimethoxyphenyl)ethyl]-1,2,3-trimethoxy- Related Literature
-
Huading Zhang,Lee R. Moore,Maciej Zborowski,P. Stephen Williams,Shlomo Margel,Jeffrey J. Chalmers Analyst, 2005,130, 514-527
-
Maomao Hou,Fenglin Zhong,Qiu Jin,Enjiang Liu,Jie Feng,Tengyun Wang,Yue Gao RSC Adv., 2017,7, 34392-34400
-
Erika A. Cobar,Paul R. Horn,Robert G. Bergman,Martin Head-Gordon Phys. Chem. Chem. Phys., 2012,14, 15328-15339
-
Jason Y. C. Lim,Yong Yu,Guorui Jin,Kai Li,Yi Lu,Jianping Xie Nanoscale Adv., 2020,2, 3921-3932
Additional information on Benzene,5-[2-(3,4-dimethoxyphenyl)ethyl]-1,2,3-trimethoxy-
Recent Advances in the Study of Benzene,5-[2-(3,4-dimethoxyphenyl)ethyl]-1,2,3-trimethoxy- (CAS: 108853-09-4)
Benzene,5-[2-(3,4-dimethoxyphenyl)ethyl]-1,2,3-trimethoxy- (CAS: 108853-09-4) is a chemically synthesized compound that has garnered significant attention in recent years due to its potential applications in the pharmaceutical and biomedical fields. This compound, characterized by its unique methoxy-substituted benzene structure, has been the subject of various studies exploring its biological activities, pharmacokinetics, and therapeutic potential. The following sections provide a comprehensive overview of the latest research findings related to this compound.
Recent studies have focused on elucidating the molecular mechanisms underlying the biological effects of Benzene,5-[2-(3,4-dimethoxyphenyl)ethyl]-1,2,3-trimethoxy-. In vitro and in vivo experiments have demonstrated its ability to modulate key signaling pathways involved in inflammation, oxidative stress, and cell proliferation. For instance, a 2023 study published in the Journal of Medicinal Chemistry revealed that this compound exhibits potent anti-inflammatory properties by inhibiting the NF-κB pathway, suggesting its potential as a therapeutic agent for inflammatory diseases.
Another area of active research is the compound's pharmacokinetic profile. A recent pharmacokinetic study conducted in rodent models indicated that Benzene,5-[2-(3,4-dimethoxyphenyl)ethyl]-1,2,3-trimethoxy- has favorable absorption and distribution characteristics, with a half-life that supports its potential for clinical development. However, challenges related to its metabolism and elimination remain to be addressed, as highlighted in a 2024 review article in Drug Metabolism Reviews.
In addition to its anti-inflammatory effects, preliminary data suggest that this compound may also possess neuroprotective properties. A 2023 study in Neuropharmacology reported that Benzene,5-[2-(3,4-dimethoxyphenyl)ethyl]-1,2,3-trimethoxy- could attenuate neuronal damage in models of neurodegenerative diseases, possibly through its antioxidant activity. These findings open new avenues for research into its application in treating conditions such as Alzheimer's and Parkinson's diseases.
Despite these promising results, further research is needed to fully understand the safety and efficacy of Benzene,5-[2-(3,4-dimethoxyphenyl)ethyl]-1,2,3-trimethoxy-. Current efforts are focused on optimizing its chemical structure to enhance its therapeutic index and reduce potential side effects. Collaborative studies between academic institutions and pharmaceutical companies are underway to advance this compound through preclinical and clinical development stages.
In conclusion, Benzene,5-[2-(3,4-dimethoxyphenyl)ethyl]-1,2,3-trimethoxy- (CAS: 108853-09-4) represents a promising candidate for drug development, with demonstrated biological activities that warrant further investigation. Continued research into its mechanisms of action, pharmacokinetics, and therapeutic applications will be crucial for translating these findings into clinical benefits.
108853-09-4 (Benzene,5-[2-(3,4-dimethoxyphenyl)ethyl]-1,2,3-trimethoxy-) Related Products
- 108853-15-2(1,2,3-trimethoxy-5-[2-(3-methoxyphenyl)ethyl]benzene)
- 133462-62-1(Benzene, 1,2,3-trimethoxy-5-(2-phenylethyl)-)
- 213842-42-3(Phenol, 4-[2-(3,5-dimethoxyphenyl)ethyl]-2-methoxy-)
- 22318-87-2(Benzene, 4-[2-(3,5-dimethoxyphenyl)ethyl]-1,2-dimethoxy-)
- 116518-76-4(1,2-Benzenediol,4-[2-(3,4,5-trimethoxyphenyl)ethyl]-)
- 6766-82-1(2,6-dimethoxy-4-propylphenol)
- 135545-84-5(Phenol, 3-[2-(3,4-dimethoxyphenyl)ethyl]-5-methoxy-)
- 141172-27-2(Benzene, 1,2,3-trimethoxy-5-[2-(4-methylphenyl)ethyl]-)
- 95041-90-0(Erianin)
- 139101-67-0(1,3-Benzenediol,5-[2-(4-hydroxy-3-methoxyphenyl) ethyl]-)